Ipsen SA - Asset Resilience Ratio
Ipsen SA (IPN) has an Asset Resilience Ratio of 21.63% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2024)
This chart shows how Ipsen SA's Asset Resilience Ratio has changed over time. Check IPN strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Ipsen SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IPN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.45 Billion | 21.16% |
| Short-term Investments | €32.30 Million | 0.47% |
| Total Liquid Assets | €1.48 Billion | 21.63% |
Asset Resilience Insights
- Good Liquidity Position: Ipsen SA maintains a healthy 21.63% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Ipsen SA Industry Peers by Asset Resilience Ratio
Compare Ipsen SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621 |
Drug Manufacturers - Specialty & Generic | 2.04% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
|
Jw Pharmac
KO:001060 |
Drug Manufacturers - Specialty & Generic | 3.65% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Samjin Pharm
KO:005500 |
Drug Manufacturers - Specialty & Generic | 0.25% |
Annual Asset Resilience Ratio for Ipsen SA (2002–2024)
The table below shows the annual Asset Resilience Ratio data for Ipsen SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.02% | €1.10 Million ≈ $1.29 Million |
€6.44 Billion ≈ $7.53 Billion |
-0.15pp |
| 2023-12-31 | 0.17% | €10.60 Million ≈ $12.39 Million |
€6.32 Billion ≈ $7.39 Billion |
-21.24pp |
| 2022-12-31 | 21.40% | €1.20 Billion ≈ $1.40 Billion |
€5.61 Billion ≈ $6.56 Billion |
+4.23pp |
| 2021-12-31 | 17.17% | €857.10 Million ≈ $1.00 Billion |
€4.99 Billion ≈ $5.83 Billion |
+16.55pp |
| 2020-12-31 | 0.62% | €26.80 Million ≈ $31.33 Million |
€4.31 Billion ≈ $5.04 Billion |
-3.96pp |
| 2019-12-31 | 4.58% | €197.20 Million ≈ $230.55 Million |
€4.31 Billion ≈ $5.04 Billion |
-1.57pp |
| 2018-12-31 | 6.15% | €207.70 Million ≈ $242.82 Million |
€3.38 Billion ≈ $3.95 Billion |
-2.98pp |
| 2017-12-31 | 9.13% | €280.60 Million ≈ $328.05 Million |
€3.07 Billion ≈ $3.59 Billion |
-5.91pp |
| 2016-12-31 | 15.04% | €364.50 Million ≈ $426.14 Million |
€2.42 Billion ≈ $2.83 Billion |
+14.69pp |
| 2015-12-31 | 0.35% | €6.80 Million ≈ $7.95 Million |
€1.94 Billion ≈ $2.27 Billion |
+0.35pp |
| 2014-12-31 | 0.01% | €100.00K ≈ $116.91K |
€1.71 Billion ≈ $2.00 Billion |
-0.01pp |
| 2013-12-31 | 0.01% | €200.00K ≈ $233.82K |
€1.57 Billion ≈ $1.83 Billion |
-0.02pp |
| 2012-12-31 | 0.03% | €516.00K ≈ $603.26K |
€1.56 Billion ≈ $1.83 Billion |
+0.03pp |
| 2011-12-31 | 0.00% | €9.00K ≈ $10.52K |
€1.63 Billion ≈ $1.91 Billion |
0.00pp |
| 2010-12-31 | 0.00% | €49.00K ≈ $57.29K |
€1.68 Billion ≈ $1.96 Billion |
-0.07pp |
| 2009-12-31 | 0.07% | €1.16 Million ≈ $1.36 Million |
€1.58 Billion ≈ $1.84 Billion |
-0.09pp |
| 2008-12-31 | 0.16% | €2.53 Million ≈ $2.96 Million |
€1.57 Billion ≈ $1.84 Billion |
-0.30pp |
| 2007-12-31 | 0.46% | €6.10 Million ≈ $7.13 Million |
€1.32 Billion ≈ $1.55 Billion |
+0.39pp |
| 2006-12-31 | 0.07% | €901.00K ≈ $1.05 Million |
€1.21 Billion ≈ $1.42 Billion |
+0.07pp |
| 2005-12-31 | 0.00% | €18.00K ≈ $21.04K |
€942.51 Million ≈ $1.10 Billion |
-11.71pp |
| 2004-12-31 | 11.71% | €72.59 Million ≈ $84.86 Million |
€619.71 Million ≈ $724.51 Million |
-1.40pp |
| 2003-12-31 | 13.12% | €87.34 Million ≈ $102.11 Million |
€665.90 Million ≈ $778.50 Million |
-3.85pp |
| 2002-12-31 | 16.97% | €112.39 Million ≈ $131.39 Million |
€662.33 Million ≈ $774.34 Million |
-- |
About Ipsen SA
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more